TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
REPL

Replimune Group Inc

Healthcare · Biotechnology

12.90$ -0.7% vs. previous close Closing price · As of: Sep 17, 2026

Investor relations

Report Dates

Investor relations overview for Replimune Group Inc (REPL): report dates, earnings surprises, earnings call transcripts and the latest headlines. The next report is scheduled for 11/05/2026.

Next report 11/05/2026
Last report 08/14/2026
Earnings surprise by quarter (%)
Q3 23 · -1.1 % 23 Q4 23 · 17.2 % 23 Q1 24 · 68.8 % 24 Q2 24 · 6.0 % 24 Q3 24 · 8.1 % 24 Q4 24 · -9.7 % 24 Q1 25 · -18.8 % 25 Q2 25 · -14.5 % 25 Q3 25 · -13.9 % 25 Q4 25 · 6.1 % 25 Q1 26 · -4.1 % 26 Q2 26 · 0.0 % 26

EPS estimate beaten

Full history 11 of 34 quarters (32%)
Last 16 quarters 7 of 16 quarters (44%)

Earnings Call Transcripts

Search all transcripts →

No transcripts yet — they will show up here automatically after the next earnings call.

News on This Stock

  • 09/16/2026 Replimune Group, Inc. (REPL): Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits · sec.gov Open ↗
  • 08/14/2026 Replimune Group, Inc. (REPL): Results of Operations and Financial Condition; Financial Statements and Exhibits · sec.gov Open ↗
  • 08/10/2026 Replimune Group, Inc. (REPL): Other Events; Financial Statements and Exhibits · sec.gov Open ↗
  • 08/07/2026 Replimune Group, Inc. (REPL): Other Events; Financial Statements and Exhibits · sec.gov Open ↗
  • 07/31/2026 Replimune Group, Inc. (REPL): Other Events; Financial Statements and Exhibits · sec.gov Open ↗
  • 07/30/2026 Replimune Group, Inc. (REPL): Regulation FD Disclosure; Financial Statements and Exhibits · sec.gov Open ↗

Automatically matched wire and portal stories; external links open the original source.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Transcripts: transcript archive

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?